Cargando…

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

Detalles Bibliográficos
Autores principales:	Ozaki, S, Handa, H, Saitoh, T, Murakami, H, Itagaki, M, Asaoku, H, Suzuki, K, Isoda, A, Matsumoto, M, Sawamura, M, Konishi, J, Sunami, K, Takezako, N, Hagiwara, S, Kuroda, Y, Chou, T, Nagura, E, Shimizu, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648525/ https://www.ncbi.nlm.nih.gov/pubmed/26383822 http://dx.doi.org/10.1038/bcj.2015.79

Ejemplares similares

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
por: Suzuki, Kenshi, et al.
Publicado: (2017)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Sasaki, M., et al.
Publicado: (2022)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM
por: Sunami, Kazutaka, et al.
Publicado: (2020)

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
por: Takezako, Naoki, et al.
Publicado: (2020)

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan
por: Miyamoto‐Nagai, Yurie, et al.
Publicado: (2022)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma
por: Abe, Yu, et al.
Publicado: (2023)

Activin A: a novel urinary biomarker of renal impairment in multiple myeloma
por: Iriuchishima, Hirono, et al.
Publicado: (2019)

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
por: Sunami, Kazutaka, et al.
Publicado: (2020)

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma
por: Abe, Yu, et al.
Publicado: (2023)

Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation
por: Takamatsu, H., et al.
Publicado: (2017)

MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression
por: Murakami, Yuki, et al.
Publicado: (2022)

Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
por: Handa, Hiroshi, et al.
Publicado: (2023)

The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma
por: Handa, Hiroshi, et al.
Publicado: (2019)

Proliferative state and radiosensitivity of human myeloma stem cells.
por: Shimizu, T., et al.
Publicado: (1982)

Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression
por: Handa, Hiroshi, et al.
Publicado: (2020)

Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma
por: Aoki, Yuka, et al.
Publicado: (2012)

Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma
por: Isoda, Atsushi, et al.
Publicado: (2014)

Correction: Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma
por: Aoki, Yuka, et al.
Publicado: (2013)

Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression
por: Ishihara, Rei, et al.
Publicado: (2023)

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
por: Narita, T, et al.
Publicado: (2015)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
por: Iida, Shinsuke, et al.
Publicado: (2019)

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial
por: Ichinohe, Tatsuo, et al.
Publicado: (2016)

Overexpression of B‐cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response
por: Tahara, Kenichi, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
por: Ozaki, Shuji, et al.
Publicado: (2014)

Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan
por: Tsukune, Yutaka, et al.
Publicado: (2017)

COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022)

The Myeloma Globulins
por: Houghton, P., et al.
Publicado: (1960)

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
por: Suzuki, Kenshi, et al.
Publicado: (2016)

The Myeloma Globulins
por: McConnell, R. J., et al.
Publicado: (1958)

Multiple myeloma presenting as bilateral orbital proptosis
por: Malik, Archana, et al.
Publicado: (2009)

Drusen-like deposits in a patient with multiple myeloma
por: Handa, S, et al.
Publicado: (2021)

GENETIC CHARACTERS OF HUMAN γ-GLOBULINS IN MYELOMA PROTEINS
por: Harboe, M., et al.
Publicado: (1962)

Gynaecomastia complicating the treatment of myeloma.
por: Large, D. M., et al.
Publicado: (1983)

DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
por: Saitoh, Takayuki, et al.
Publicado: (2021)

Multiple Myeloma—An In Vitro Study
por: Richmond, H. G., et al.
Publicado: (1961)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oh3s035rhaqkm62l83lm1l98fc